SIRT7 and prostate cancer: The knock down of SIRT7 inhibits the migration of two androgen-independent prostate cancer cells (DU145 and PC3), although the overexpression of the native protein, but not the mutated form, promotes cell migration and invasion of the poorly aggressive, androgen-dependent LNCaP cell line.